Developer docs
API playgroundTry for free, no card

Search company profiles

3billion

Full company profile

uuid00023wu

Namestring
3billion
Legal namestring
3billion, Inc.
Websiteurl
3billion.io
Company typeenum
Public
Founded yearint
2016
Descriptiontext

3billion, Inc. is a Seoul-headquartered, KOSDAQ-listed (ticker: 3BIONE) clinical genomics company founded in October 2016 that delivers AI-powered rare-disease diagnostics to healthcare providers and patients globally. Its core offering is a sequencing-and-interpretation stack: 3B-GENOME (WGS) and 3B-EXOME (WES) diagnostic tests with a 5-week turnaround, 3B-VARIANT (Sanger confirmation), and 3B-INTERPRETER for labs that perform their own sequencing and submit FASTQ data. The diagnostic engine rests on four proprietary AI systems — EVIDENCE for ACMG-aligned variant interpretation (98.4% sensitivity, 99.9% specificity), 3Cnet for variant pathogenicity prediction (2.2x higher sensitivity than alternatives), the GEBRA SaaS platform for end-to-end interpretation (99.4% accuracy, 20-minute WES turnaround), and MIN-T for AI-driven drug discovery (95% synthesis confirmability). All diagnostic tests include automated, weekly reanalysis of negative and inconclusive cases at no additional cost, generating 954+ additional diagnoses since 2024.

The company monetizes through a mix of one-time test fees (B2B via a healthcare-provider portal serving 2,100+ providers and 790+ institutions across 75+ countries), recurring SaaS subscriptions for GEBRA, an End the Diagnostic Odyssey grant program providing free WGS/WES to eligible pediatric patients, and emerging pharma collaborations. The 2025-2026 product launches (Family Insight Test in March 2026, 3B-NEO genomic newborn screening covering 595 genes in June 2026) extend the platform from rare-disease diagnosis into proactive reproductive and newborn health. With a $225M USD post-IPO capital raise in April 2026 and a $8.1M US subsidiary buildout in Austin, Texas (3billion US, Inc., 200 jobs planned by 2026), the company is scaling from a Korea-export diagnostic model into a multi-region, multi-product clinical AI platform backed by CAP, CLIA, ISO/IEC 27001:2022, and HIPAA-on-AWS compliance.

Short descriptiontext

3billion is an AI-powered genomic diagnostics company providing rare disease identification, family-based testing, and newborn screening through WGS/WES sequencing, proprietary variant interpretation (EVIDENCE, 3Cnet, GEBRA), and a SaaS platform, serving 2,100+ healthcare providers across 75+ countries.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersSeoul, South Korea
HQ citystring
Seoul
HQ countrystring
South Korea
HQ regionstring
Asia
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
rare disease diagnostics, clinical genomic testing, AI variant interpretation, whole genome sequencing, newborn genetic screening
Industry5 codes
PRIMARYHLAFAMAH
Genetic & Prenatal Testing Laboratories
SECONDARYHLAAALAD
Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics)
SECONDARYHLAAALAJ
Prenatal, Newborn & Reproductive Diagnostics (NIPT, IVF/PGT, newborn screening)
SECONDARYHLAHAAAI
Genetic, Cytogenetic & Prenatal Screening IVD
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
SECONDARYHLAGAEAD
Genomics & Molecular Diagnostics (Trial Support)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)
NAICS code2 codes
  • Medical Laboratories621511
  • Medical and Diagnostic Laboratories6215
SIC code2 codes
  • Services-Medical Laboratories8071
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
Clinical Genomics & Rare Disease Diagnostics
GTM motion4 records

Each record includes

Type, Description, Source

Revenue model7 records
1Whole Genome Sequencing (3B-GENOME)
TypeOne Time License
Description

Full WGS-based genetic testing service with TAT of 5 weeks, including automated reanalysis. Detects SNV, INDEL, SV (including CNV), and mitochondrial DNA variants. Primary diagnostic service for complex rare disease cases.

3billion.io
2Whole Exome Sequencing (3B-EXOME)
TypeOne Time License
Description

WES-based genetic testing service with TAT of 5 weeks, including automated reanalysis. Covers approximately 20,000 genes with enhanced depth and coverage (Boosted Exome V2 with up to 2000x mitochondrial coverage). Primary first-line test for rare disease diagnosis.

3billion.io
33B-VARIANT (Sanger Sequencing)
TypeOne Time License
Description

Targeted Sanger sequencing service to reconfirm specific variants detected by 3B-GENOME or 3B-EXOME. TAT of 2 weeks. Used for family member confirmation and family planning.

3billion.io
43B-INTERPRETER
TypeOne Time License
Description

Data-based genomic analysis and interpretation service from uploaded FASTQ data. TAT of 2 weeks. Revenue stream from labs sending raw sequencing data for clinical reporting.

3billion.io
53B-NEO Newborn Screening
TypeOne Time License
Description

Genomic newborn screening service covering 595 genes (WES or WGS options) with TAT of ~2 weeks. Available as standard (WES) or premium (WGS) plans. Targets maternity hospitals, obstetrics practices, pediatric clinics, and families. Launched June 2026.

3billion.io
6Family Insight Test
TypeOne Time License
Description

Family-based WGS/WES precision genomic testing service launched March 2026. Adds carriership findings for families facing reproductive challenges or inherited risks. Covers reproductive loss, genetic legacy, alternative path, and consanguinity use cases.

prnewswire.com
7GEBRA SaaS Platform
TypeSubscription Recurring
Description

AI-powered variant interpretation SaaS platform offered to medical geneticists and diagnostic labs. Implements HIPAA-compliant cloud-native architecture on AWS. Revenue from SaaS subscription/licensing to clinical labs and institutions.

3billion.io
Marketing channels8 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels5 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Pricing details1 tier
1End the Diagnostic Odyssey Grant — free WGS/WES testing for eligible pediatric patients
ModelOtherBilling cadenceMulti-year contract
Notes

Grant program providing free whole genome sequencing or whole exome sequencing with clinical-grade reports for pediatric patients meeting eligibility criteria (intellectual disability, developmental delay, neuromuscular disorders, white matter disease, inborn errors of metabolism, cohort aged 18 and below). Application process takes 2-3 months.

3billion.io
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 7 records shown
13B-GENOME
Description

Whole genome sequencing-based genetic testing service

3billion.io
+6 more records
Core offering1 text field

3billion provides AI-powered clinical genomic testing and interpretation services for rare disease diagnosis and newborn screening. Its core offerings include whole-genome sequencing (3B-GENOME), whole-exome sequencing (3B-EXOME), targeted Sanger variant confirmation (3B-VARIANT), automated variant interpretation (3B-INTERPRETER), and a family/newborn screening panel (3B-NEO). The company also licenses GEBRA, a SaaS variant interpretation and clinical reporting platform, to external diagnostic laboratories.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 8 values shown
  • 98.4% sensitivity and 99.9% specificity in variant interpretation (EVIDENCE vs ClinVar)
+7 more records
Product overview1 text field

3billion offers a comprehensive genetic testing platform consisting of diagnostic sequencing products (3B-GENOME for WGS, 3B-EXOME for WES, 3B-VARIANT for Sanger sequencing), data interpretation services (3B-INTERPRETER for uploaded data analysis), and the AI-powered GEBRA™ interpretation platform. The portfolio expands into proactive healthcare with 3B-NEO genomic newborn screening (595 genes) and the Family Insight Test for family-based analysis. Core AI technologies include EVIDENCE (automated variant interpretation), 3Cnet (pathogenicity prediction), and MIN-T (drug discovery). All diagnostic products include automated reanalysis at no additional cost. Services are accessed through a web portal with results delivered within 2-5 weeks depending on test type.

Product and service7 records
13B-GENOME
CategoryClinical genomic testing service
Description

Clinical whole-genome sequencing (WGS) test for rare disease diagnosis, using AI-augmented variant interpretation and ACMG-aligned reporting for healthcare providers.

23B-EXOME
CategoryClinical genomic testing service
Description

Clinical whole-exome sequencing (WES) test for rare disease diagnosis with AI-driven interpretation, targeting pediatric and neurology genetic cases.

33B-VARIANT
CategoryClinical genomic testing service
Description

Targeted Sanger sequencing confirmation service for previously identified variants, used by clinicians for orthogonal validation of NGS findings.

43B-INTERPRETER
CategoryClinical interpretation service
Description

Automated clinical variant interpretation service that applies ACMG guidelines and 3billion's AI models to produce clinically actionable reports for healthcare providers.

53B-NEO
CategoryNewborn screening service
Description

Newborn genetic screening panel for early detection of treatable inherited disorders, offered to families and pediatric care providers.

6Family Insight Test
CategoryClinical genomic testing service
Description

Family-based genetic testing service that analyzes variants across multiple family members (typically trio analysis) to resolve variants of uncertain significance in rare disease cases.

7GEBRA
CategoryLaboratory software (SaaS)
Description

SaaS variant interpretation and clinical reporting platform licensed to external diagnostic laboratories, providing ACMG-classified variant interpretation, automated clinical report generation, and reanalysis workflows.

Scale indicator14 records

Each record includes

Type, Value, Description, Source

Partnership9 partners
1CEPCAL (Colaborativa para Enfermedades Poco Frecuentes en el Caribe y América Latina)
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2026-06-01
Description

3billion announced participation in CEPCAL 2026, taking place June 17-19, 2026 in Antigua, Guatemala. CEPCAL is a collaborative initiative for rare diseases in the Caribbean and Latin America. 3billion will connect with clinicians, researchers, laboratory professionals, and healthcare partners from Latin America and the Caribbean to explore how genetic testing can support their practice or research.

prnewswire.com
2European Society of Human Genetics (ESHG)
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2026-06-01
Description

3billion attending ESHG Conference 2026 in Gothenburg, Sweden (June 13-16, Booth #620). Presenting comprehensive genetic testing services, 3B-NEO newborn screening, and Family Insight Test. Opportunity to connect with clinical geneticists and genomic specialists across Europe.

prnewswire.com
3Genomic and Genetic Technologies in Clinical Practice Conference 2026
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2026-06-01
Description

3billion attending conference at Narxoz Business School in Almaty, Kazakhstan (June 3-4, 2026). Two presentations: 'Expanding Rare Disease Diagnosis: 3billion's Evolving Genetic Solutions' by Minsoo Kim and 'The Clinical Impact of Reanalysis in Rare Diseases' by Yoo Hyun Kim.

prnewswire.com
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2026-03-11
Description

3billion showcased its AI-powered variant interpretation platform GEBRA at ACMG 2026 conference in Baltimore, Maryland (March 2026). Demonstrated the platform's capabilities to clinical geneticists and researchers worldwide as part of its efforts to expand global presence and strengthen technical leadership in genetic diagnostics.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

3billion selected as first official laboratory partner in Asia for Genetic Alliance's iHope program (March 2026). Provides precision diagnostics for pediatric rare disease patients in developing nations, helping reduce prolonged diagnostic odysseys. 3billion contributes its AI-powered variant interpretation platform (GEBRA) and operational infrastructure spanning 75+ countries. Expands 3billion's role in the global rare disease diagnostic ecosystem and advances equitable access to precision medicine worldwide.

Strategic tierCoreTypeTechnology or Integration
Description

3billion implemented GEBRA as a SaaS platform using AWS cloud infrastructure with HIPAA compliance. Leveraged AWS cloud security tools to address varying data governance standards across countries and established a cloud-native environment for processing large-scale genomic data. Participated as speaker at AWS HealthTech Global Expansion Seminar 2026 (April 28) sharing its experience with global market expansion. Also showcased AI genomic interpretation SaaS at AWS Public Sector Day 2025.

7Embassy of Argentina in Seoul
Strategic tierStrategicTypeStrategic or Co-development Partner
Description

3billion conducted an official visit to the Embassy of Argentina in Seoul (April 2026) to discuss strategic cooperation aimed at expanding precision medicine networks in South America. Meeting with Ambassador Darío Celaya focused on building equitable medical systems and delivering diagnostic solutions to rare disease patients in Argentina and beyond. Plans to strengthen partnerships advancing practical diagnostic solutions in the region.

3billion.io
8Over 400 Global Healthcare and Research Institutions
Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

3billion collaborates with over 400 healthcare and research institutions globally including Seoul National University Hospital, Samsung Changwon Hospital, Hospital Kuala Lumpur, Hospital Regional de Antofagasta, Universidade Federal de Sao Paulo, University of Malaya, and others across 70+ countries. These institutions order genetic tests through the 3billion portal and serve as the primary distribution channel for diagnostic services.

3billion.io
Strategic tierStrategicTypeOthers
Description

Austin City Council approved a 10-year expansion agreement with 3billion US, Inc. in February 2026, involving $8.1M capital investment and creation of 200 full-time jobs. City offered $200,000 incentive ($1,000 per job created) to establish the first North American genetic testing laboratory in Austin.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight10 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Centogene is a rare disease diagnostics company with similar focus on rare disease genetic testing, biomarker discovery, and global operations. Direct competitor in rare disease genomics with parallel target market of patients and pharmaceutical partners.

TypeDirect peer
Description

Sophia Genetics is an AI-driven genomic and clinical data analysis company serving hospitals and labs. Direct peer in AI-powered genomic interpretation SaaS with similar business model of providing variant interpretation technology to clinical institutions.

TypeDirect peer
Description

GeneDx is a leading US-based clinical genetic testing company specializing in rare disease diagnosis using whole exome and genome sequencing. Direct competitor in rare disease genetic diagnostics with similar AI-driven interpretation focus and established US market presence.

TypeBroad incumbent
Description

Ambry Genetics (acquired by Konica Minolta) is an established US clinical genetic testing lab offering comprehensive hereditary disease testing. Broad incumbent with larger scale and broader test menu including rare disease panels.

TypeDirect peer
Description

PreventionGenetics is a clinical DNA testing laboratory offering whole genome, exome, and targeted genetic tests for rare disorders. Direct peer in clinical genetic testing with focus on hereditary and rare disease diagnostics.

TypeDirect peer
Description

Invitae, acquired by Labcorp, was a major genetic testing company offering comprehensive genetic tests including rare disease panels. Direct competitor in clinical genetic testing with much larger US footprint and broader test menu.

TypeBroad incumbent
Description

Myriad Genetics is a major genetic testing and precision medicine company with a long history in hereditary cancer and other genetic tests. Broad incumbent with diversified product portfolio and established US market presence.

TypeBroad incumbent
Description

Illumina is the dominant DNA sequencing technology provider whose platforms 3billion uses (NovaSeq X). Broad incumbent in genomics ecosystem; a critical technology partner and indirect competitor as Illumina expands into clinical diagnostics.

TypeDirect peer
Description

Variantyx is a clinical genetic testing company focused on rare disease diagnosis using whole genome sequencing and AI-driven variant interpretation. Direct peer with similar focus on rare disease and comparable technology approach.

TypeDirect peer
Description

Natera is a US-based genetic testing company offering reproductive and oncology genetic tests. Direct peer in advanced genetic testing with strong AI/machine learning capabilities and similar technology-driven value proposition.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers20 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability6 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance4 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors15 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

3billion

Clinical Genomics & Rare Disease Diagnostics3billion.io

3billion is an AI-powered genomic diagnostics company providing rare disease identification, family-based testing, and newborn screening through WGS/WES sequencing, proprietary variant interpretation (EVIDENCE, 3Cnet, GEBRA), and a SaaS platform, serving 2,100+ healthcare providers across 75+ countries.

What 3billion does

3billion, Inc. is a Seoul-headquartered, KOSDAQ-listed (ticker: 3BIONE) clinical genomics company founded in October 2016 that delivers AI-powered rare-disease diagnostics to healthcare providers and patients globally. Its core offering is a sequencing-and-interpretation stack: 3B-GENOME (WGS) and 3B-EXOME (WES) diagnostic tests with a 5-week turnaround, 3B-VARIANT (Sanger confirmation), and 3B-INTERPRETER for labs that perform their own sequencing and submit FASTQ data. The diagnostic engine rests on four proprietary AI systems — EVIDENCE for ACMG-aligned variant interpretation (98.4% sensitivity, 99.9% specificity), 3Cnet for variant pathogenicity prediction (2.2x higher sensitivity than alternatives), the GEBRA SaaS platform for end-to-end interpretation (99.4% accuracy, 20-minute WES turnaround), and MIN-T for AI-driven drug discovery (95% synthesis confirmability). All diagnostic tests include automated, weekly reanalysis of negative and inconclusive cases at no additional cost, generating 954+ additional diagnoses since 2024.

The company monetizes through a mix of one-time test fees (B2B via a healthcare-provider portal serving 2,100+ providers and 790+ institutions across 75+ countries), recurring SaaS subscriptions for GEBRA, an End the Diagnostic Odyssey grant program providing free WGS/WES to eligible pediatric patients, and emerging pharma collaborations. The 2025-2026 product launches (Family Insight Test in March 2026, 3B-NEO genomic newborn screening covering 595 genes in June 2026) extend the platform from rare-disease diagnosis into proactive reproductive and newborn health. With a $225M USD post-IPO capital raise in April 2026 and a $8.1M US subsidiary buildout in Austin, Texas (3billion US, Inc., 200 jobs planned by 2026), the company is scaling from a Korea-export diagnostic model into a multi-region, multi-product clinical AI platform backed by CAP, CLIA, ISO/IEC 27001:2022, and HIPAA-on-AWS compliance.

3billion firmographics

Firmographics
Name
3billion
Legal name
3billion, Inc.
Website
https://3billion.io
Company type
Public
Founded year
2016
Operating status
Operating
Headcount range
51–100 employees
Short description
3billion is an AI-powered genomic diagnostics company providing rare disease identification, family-based testing, and newborn screening through WGS/WES sequencing, proprietary variant interpretation (EVIDENCE, 3Cnet, GEBRA), and a SaaS platform, serving 2,100+ healthcare providers across 75+ countries.
Ownership category
akta.pro rank

3billion industry classification

Industry
Product category
Clinical Genomics & Rare Disease Diagnostics
NAICS
Medical Laboratories (621511), Medical and Diagnostic Laboratories (6215)
SIC
Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLAFAMAH
Genetic & Prenatal Testing Laboratories
SECONDARYHLAAALAD
Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics)
SECONDARYHLAAALAJ
Prenatal, Newborn & Reproductive Diagnostics (NIPT, IVF/PGT, newborn screening)
SECONDARYHLAHAAAI
Genetic, Cytogenetic & Prenatal Screening IVD
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
SECONDARYHLAGAEAD
Genomics & Molecular Diagnostics (Trial Support)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)

Keywords

  • Rare disease diagnostics
  • Clinical genomic testing
  • AI variant interpretation
  • Whole genome sequencing
  • Newborn genetic screening

Where 3billion is headquartered

Location

Headquarters

HQ city
Seoul
HQ country
South Korea
HQ region
Asia

Offices2 records

Markets served

3billion business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Whole Genome Sequencing (3B-GENOME): Full WGS-based genetic testing service with TAT of 5 weeks, including automated reanalysis. Detects SNV, INDEL, SV (including CNV), and mitochondrial DNA variants. Primary diagnostic service for complex rare disease cases.
  2. Whole Exome Sequencing (3B-EXOME): WES-based genetic testing service with TAT of 5 weeks, including automated reanalysis. Covers approximately 20,000 genes with enhanced depth and coverage (Boosted Exome V2 with up to 2000x mitochondrial coverage). Primary first-line test for rare disease diagnosis.
  3. 3B-VARIANT (Sanger Sequencing): Targeted Sanger sequencing service to reconfirm specific variants detected by 3B-GENOME or 3B-EXOME. TAT of 2 weeks. Used for family member confirmation and family planning.
  4. 3B-INTERPRETER: Data-based genomic analysis and interpretation service from uploaded FASTQ data. TAT of 2 weeks. Revenue stream from labs sending raw sequencing data for clinical reporting.
  5. 3B-NEO Newborn Screening: Genomic newborn screening service covering 595 genes (WES or WGS options) with TAT of ~2 weeks. Available as standard (WES) or premium (WGS) plans. Targets maternity hospitals, obstetrics practices, pediatric clinics, and families. Launched June 2026.
  6. Family Insight Test: Family-based WGS/WES precision genomic testing service launched March 2026. Adds carriership findings for families facing reproductive challenges or inherited risks. Covers reproductive loss, genetic legacy, alternative path, and consanguinity use cases.
  7. GEBRA SaaS Platform: AI-powered variant interpretation SaaS platform offered to medical geneticists and diagnostic labs. Implements HIPAA-compliant cloud-native architecture on AWS. Revenue from SaaS subscription/licensing to clinical labs and institutions.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractEnd the Diagnostic Odyssey Grant — free WGS/WES testing for eligible pediatric patients

Go-to-market motion4 records

Distribution channels5 records

Marketing channels8 records

3billion product offering

Product offering

Core offering

3billion provides AI-powered clinical genomic testing and interpretation services for rare disease diagnosis and newborn screening. Its core offerings include whole-genome sequencing (3B-GENOME), whole-exome sequencing (3B-EXOME), targeted Sanger variant confirmation (3B-VARIANT), automated variant interpretation (3B-INTERPRETER), and a family/newborn screening panel (3B-NEO). The company also licenses GEBRA, a SaaS variant interpretation and clinical reporting platform, to external diagnostic laboratories.

Product overview

3billion offers a comprehensive genetic testing platform consisting of diagnostic sequencing products (3B-GENOME for WGS, 3B-EXOME for WES, 3B-VARIANT for Sanger sequencing), data interpretation services (3B-INTERPRETER for uploaded data analysis), and the AI-powered GEBRA™ interpretation platform. The portfolio expands into proactive healthcare with 3B-NEO genomic newborn screening (595 genes) and the Family Insight Test for family-based analysis. Core AI technologies include EVIDENCE (automated variant interpretation), 3Cnet (pathogenicity prediction), and MIN-T (drug discovery). All diagnostic products include automated reanalysis at no additional cost. Services are accessed through a web portal with results delivered within 2-5 weeks depending on test type.

Differentiator

Problem solved

Functional benefit

Brands

  • 3B-GENOME: Whole genome sequencing-based genetic testing service
  • 3B-EXOME
  • 3B-VARIANT
  • 3B-INTERPRETER
  • GEBRA
  • 3B-NEO
  • Family Insight Test

Products and services

  • 3B-GENOME Clinical whole-genome sequencing (WGS) test for rare disease diagnosis, using AI-augmented variant interpretation and ACMG-aligned reporting for healthcare providers.
  • 3B-EXOME Clinical whole-exome sequencing (WES) test for rare disease diagnosis with AI-driven interpretation, targeting pediatric and neurology genetic cases.
  • 3B-VARIANT Targeted Sanger sequencing confirmation service for previously identified variants, used by clinicians for orthogonal validation of NGS findings.
  • 3B-INTERPRETER Automated clinical variant interpretation service that applies ACMG guidelines and 3billion's AI models to produce clinically actionable reports for healthcare providers.
  • 3B-NEO Newborn genetic screening panel for early detection of treatable inherited disorders, offered to families and pediatric care providers.
  • Family Insight Test Family-based genetic testing service that analyzes variants across multiple family members (typically trio analysis) to resolve variants of uncertain significance in rare disease cases.
  • GEBRA SaaS variant interpretation and clinical reporting platform licensed to external diagnostic laboratories, providing ACMG-classified variant interpretation, automated clinical report generation, and reanalysis workflows.

Quantifiable outcome

  • 98.4% sensitivity and 99.9% specificity in variant interpretation (EVIDENCE vs ClinVar)
  • +7 more outcomes

Companies that use 3billion

Customer profile

Named customers20 records

Segments5 records

Ideal customer profiles4 records

3billion technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability6 records

Feature6 records

3billion partnerships and signals

Strategic signal

Partnerships

Nine partnerships are on record, tiered minor, core and strategic.

  • CEPCAL (Colaborativa para Enfermedades Poco Frecuentes en el Caribe y América Latina)minorStrategic or Co-development Partner · 1 June 20263billion announced participation in CEPCAL 2026, taking place June 17-19, 2026 in Antigua, Guatemala. CEPCAL is a collaborative initiative for rare diseases in the Caribbean and Latin America. 3billion will connect with clinicians, researchers, laboratory professionals, and healthcare partners from Latin America and the Caribbean to explore how genetic testing can support their practice or research.
  • European Society of Human Genetics (ESHG)minorStrategic or Co-development Partner · 1 June 20263billion attending ESHG Conference 2026 in Gothenburg, Sweden (June 13-16, Booth #620). Presenting comprehensive genetic testing services, 3B-NEO newborn screening, and Family Insight Test. Opportunity to connect with clinical geneticists and genomic specialists across Europe.
  • Genomic and Genetic Technologies in Clinical Practice Conference 2026minorStrategic or Co-development Partner · 1 June 20263billion attending conference at Narxoz Business School in Almaty, Kazakhstan (June 3-4, 2026). Two presentations: 'Expanding Rare Disease Diagnosis: 3billion's Evolving Genetic Solutions' by Minsoo Kim and 'The Clinical Impact of Reanalysis in Rare Diseases' by Yoo Hyun Kim.
  • ACMG (American College of Medical Genetics and Genomics)minorStrategic or Co-development Partner · 11 March 20263billion showcased its AI-powered variant interpretation platform GEBRA at ACMG 2026 conference in Baltimore, Maryland (March 2026). Demonstrated the platform's capabilities to clinical geneticists and researchers worldwide as part of its efforts to expand global presence and strengthen technical leadership in genetic diagnostics.
  • Genetic Alliance (iHope Program)coreStrategic or Co-development Partner3billion selected as first official laboratory partner in Asia for Genetic Alliance's iHope program (March 2026). Provides precision diagnostics for pediatric rare disease patients in developing nations, helping reduce prolonged diagnostic odysseys. 3billion contributes its AI-powered variant interpretation platform (GEBRA) and operational infrastructure spanning 75+ countries. Expands 3billion's role in the global rare disease diagnostic ecosystem and advances equitable access to precision medicine worldwide.
  • Amazon Web Services (AWS)coreTechnology or Integration3billion implemented GEBRA as a SaaS platform using AWS cloud infrastructure with HIPAA compliance. Leveraged AWS cloud security tools to address varying data governance standards across countries and established a cloud-native environment for processing large-scale genomic data. Participated as speaker at AWS HealthTech Global Expansion Seminar 2026 (April 28) sharing its experience with global market expansion. Also showcased AI genomic interpretation SaaS at AWS Public Sector Day 2025.
  • Embassy of Argentina in SeoulstrategicStrategic or Co-development Partner3billion conducted an official visit to the Embassy of Argentina in Seoul (April 2026) to discuss strategic cooperation aimed at expanding precision medicine networks in South America. Meeting with Ambassador Darío Celaya focused on building equitable medical systems and delivering diagnostic solutions to rare disease patients in Argentina and beyond. Plans to strengthen partnerships advancing practical diagnostic solutions in the region.
  • Over 400 Global Healthcare and Research InstitutionscoreChannel Partner/ Reseller/ Distributor3billion collaborates with over 400 healthcare and research institutions globally including Seoul National University Hospital, Samsung Changwon Hospital, Hospital Kuala Lumpur, Hospital Regional de Antofagasta, Universidade Federal de Sao Paulo, University of Malaya, and others across 70+ countries. These institutions order genetic tests through the 3billion portal and serve as the primary distribution channel for diagnostic services.
  • City of Austin, TexasstrategicOthersAustin City Council approved a 10-year expansion agreement with 3billion US, Inc. in February 2026, involving $8.1M capital investment and creation of 200 full-time jobs. City offered $200,000 incentive ($1,000 per job created) to establish the first North American genetic testing laboratory in Austin.

Scale indicators14 records

Recent moves8 records

Expansion highlights10 records

3billion competitors and assessment

Company assessment

Direct peers

  • Centogene: Centogene is a rare disease diagnostics company with similar focus on rare disease genetic testing, biomarker discovery, and global operations. Direct competitor in rare disease genomics with parallel target market of patients and pharmaceutical partners.
  • Sophia Genetics: Sophia Genetics is an AI-driven genomic and clinical data analysis company serving hospitals and labs. Direct peer in AI-powered genomic interpretation SaaS with similar business model of providing variant interpretation technology to clinical institutions.
  • GeneDx: GeneDx is a leading US-based clinical genetic testing company specializing in rare disease diagnosis using whole exome and genome sequencing. Direct competitor in rare disease genetic diagnostics with similar AI-driven interpretation focus and established US market presence.
  • PreventionGenetics: PreventionGenetics is a clinical DNA testing laboratory offering whole genome, exome, and targeted genetic tests for rare disorders. Direct peer in clinical genetic testing with focus on hereditary and rare disease diagnostics.
  • Invitae (now Labcorp): Invitae, acquired by Labcorp, was a major genetic testing company offering comprehensive genetic tests including rare disease panels. Direct competitor in clinical genetic testing with much larger US footprint and broader test menu.
  • Variantyx: Variantyx is a clinical genetic testing company focused on rare disease diagnosis using whole genome sequencing and AI-driven variant interpretation. Direct peer with similar focus on rare disease and comparable technology approach.
  • Natera: Natera is a US-based genetic testing company offering reproductive and oncology genetic tests. Direct peer in advanced genetic testing with strong AI/machine learning capabilities and similar technology-driven value proposition.

Broad incumbents

  • Ambry Genetics: Ambry Genetics (acquired by Konica Minolta) is an established US clinical genetic testing lab offering comprehensive hereditary disease testing. Broad incumbent with larger scale and broader test menu including rare disease panels.
  • Myriad Genetics: Myriad Genetics is a major genetic testing and precision medicine company with a long history in hereditary cancer and other genetic tests. Broad incumbent with diversified product portfolio and established US market presence.
  • Illumina: Illumina is the dominant DNA sequencing technology provider whose platforms 3billion uses (NovaSeq X). Broad incumbent in genomics ecosystem; a critical technology partner and indirect competitor as Illumina expands into clinical diagnostics.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks5 records

Key highlights6 records

Customer concentration

3billion social profiles

Digital presence

3billion compliance and trust

Trust signal

Compliance4 records

3billion financial estimates

Financial estimate

Revenue estimate

Valuation estimate

3billion leadership team

Management profile

Number of profiles

Profiles3 records

3billion subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

3billion funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors15 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

3billion M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about 3billion

What does 3billion do?

3billion provides AI-powered clinical genomic testing and interpretation services for rare disease diagnosis and newborn screening. Its core offerings include whole-genome sequencing (3B-GENOME), whole-exome sequencing (3B-EXOME), targeted Sanger variant confirmation (3B-VARIANT), automated variant interpretation (3B-INTERPRETER), and a family/newborn screening panel (3B-NEO). The company also licenses GEBRA, a SaaS variant interpretation and clinical reporting platform, to external diagnostic laboratories.

Is 3billion a public or private company?

3billion is a public company. It is classified as public and is currently operating.

When was 3billion founded?

3billion was founded in 2016. It employs 51 to 100 people.

Where is 3billion based?

3billion is headquartered in Seoul, South Korea, in the Asia region.

How does 3billion make money?

Seven revenue lines are on record. Whole Genome Sequencing (3B-GENOME) is the primary driver. The others are whole Exome Sequencing (3B-EXOME), 3B-VARIANT (Sanger Sequencing), 3B-INTERPRETER, 3B-NEO Newborn Screening, family Insight Test and GEBRA SaaS Platform.

Who are 3billion's main competitors?

Direct peers on record are Centogene, Sophia Genetics, GeneDx, PreventionGenetics, Invitae (now Labcorp), Variantyx and Natera. Broad incumbents are Ambry Genetics, Myriad Genetics and Illumina.

Does 3billion have an API?

No public API is recorded for 3billion.

What industry is 3billion in?

3billion's product category is Clinical Genomics & Rare Disease Diagnostics. Its primary akta.pro industry code is HLAFAMAH, Genetic & Prenatal Testing Laboratories, with a secondary code of HLAAALAD, Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics). Its NAICS code is 621511 and its SIC code is 8071.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Business & FinancialDeeplife And 3Billion Partner To Discover Small-Molecule Therapeutics Against Genetic Modifier Targets Across Multiple DiseasesDeepLife and 3billion announced a co-development collaboration to discover small-molecule therapeutics against genetic modifier targets across multiple diseases. The partnership combines DeepLife's TwinCell virtual cell technology with 3billion's genomic insights and AI-driven medicinal chemistry. The companies aim to advance a portfolio of programs through preclinical and IND-enabling development.Naver10 Years of Answers: Discover How Three Billion Transformed Rare Disease Testing3billion, an AI-powered rare disease diagnostics firm, marked its 10th anniversary with a campaign. It has provided test results to over 100,000 patients across 75 countries, with 2025 revenue of 11.7 billion KRW. The company plans to expand into early detection and drug development.The future of tradingSouth Korea’s NPS cuts 3billion stake to 4.02% from 5.06% filing showsSouth Korea's National Pension Service cut its stake in 3billion to 4.02% from 5.06%, selling 271,776 shares on-market. The filing, dated July 14, 2026, cites passive investment as the holding purpose.Venturesquare쓰리빌리언, 미국 첫 임상검사실 구축 맡길 전문가 영입…CLIA·CAP 인증 추진Three Billion, an AI-based rare disease diagnostic company, hired Erik Zmuda as vice president of its U.S. subsidiary to oversee its first overseas clinical laboratory in Austin. Zmuda will pursue CLIA and CAP accreditation and manage operations from sample reception to sequencing and analysis. The company plans to gradually secure U.S. testing infrastructure and enter the insurance market.Venturesquare쓰리빌리언, 희귀질환 진단 AI를 치료제 개발로…80억원 규모 ARPA-H 공동연구Three Billion, an AI-based rare disease diagnostic company, was selected as a joint R&D partner for a Korean ARPA-H project with KAIST and Asan Medical Center. The project, funded up to 800 million KRW from 2026 to 2030, aims to build an ASO therapeutic development platform and conduct preclinical verification. It expands from N-of-1 to N-of-many, identifying patient groups with similar genetic mutations.Venturesquare쓰리빌리언, 신생아 유전체 검사 중남미 첫발…도미니카공화국 3B-NEO 공급Three Billion signed a supply contract for its newborn genomic screening test 3B-NEO with Fetal Plus in the Dominican Republic, its first Latin America deal. The test analyzes 704 genes for rare genetic diseases in newborns within 90 days. The company plans to expand clinical use and reach other Latin American institutions.VenturesquareAI genetic mutation interpretation reduced from 120 minutes to 5 minutes... Three Billion 'Zebra', used and evaluated in 30 countries.Three Billion announced that its AI genetic variant analysis platform Zebra is used or evaluated in over 30 countries, including institutions in Korea, Singapore, Taiwan, and Morocco. Internal evaluation shows analysis time reduced from about 120 minutes to 5 minutes, a 24-fold speedup. The company also passed AWS FTR and expanded online demo and webinar access.VenturesquareRemaining child samples, family genomes as clues... Three Billion 'Family Insight'Three Billion announced the Family Insight Test, a family-unit precision genomic test, at a symposium on the 6th. The test analyzes family genomes, clinical history, and phenotypes to estimate genetic causes and recurrence risk, even when child samples are unavailable. The company plans to expand cooperation with domestic medical institutions.VenturesquareThe Military Manpower Administration met with a specialized researcher to find three billion... Listening to opinions from the AI research field.The Military Manpower Administration met with researchers at AI-based rare disease company Three Billion on the 21st to discuss R&D environment and system operations. The government plans to expand support for AI and semiconductor research personnel through the 2027 selection criteria, giving priority to AI-related master's-level researchers.Clinical Lab Products3billion Launches Genomic Newborn Screening Service for 595 Genetic Conditions3billion, a genomic diagnostics company headquartered in Seoul, South Korea, with operations in Austin, Texas, launched 3B-NEO, a genomic newborn screening service that uses whole exome and whole genome sequencing to identify genetic risks for 595 serious childhood-onset conditions before symptoms appear. The service offers two testing options—a standard whole-exome sequencing test and a premium whole-genome sequencing test—with results delivered within approximately two weeks. The company is preparing local laboratory operations in Austin to support US healthcare providers as part of its strategy to expand from rare disease diagnosis into proactive genomic healthcare.